HK1199047A1 - Il-31 monoclonal antibodies and methods of use il-31 - Google Patents

Il-31 monoclonal antibodies and methods of use il-31

Info

Publication number
HK1199047A1
HK1199047A1 HK14112678.8A HK14112678A HK1199047A1 HK 1199047 A1 HK1199047 A1 HK 1199047A1 HK 14112678 A HK14112678 A HK 14112678A HK 1199047 A1 HK1199047 A1 HK 1199047A1
Authority
HK
Hong Kong
Prior art keywords
methods
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
HK14112678.8A
Other languages
English (en)
Chinese (zh)
Inventor
Anthony W Siadak
Janine Bilsborough
Shirley Rene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1199047A1 publication Critical patent/HK1199047A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14112678.8A 2006-09-01 2014-12-17 Il-31 monoclonal antibodies and methods of use il-31 HK1199047A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82440306P 2006-09-01 2006-09-01
US89079207P 2007-02-20 2007-02-20

Publications (1)

Publication Number Publication Date
HK1199047A1 true HK1199047A1 (en) 2015-06-19

Family

ID=38752366

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112678.8A HK1199047A1 (en) 2006-09-01 2014-12-17 Il-31 monoclonal antibodies and methods of use il-31

Country Status (19)

Country Link
US (6) US8466262B2 (xx)
EP (3) EP2759549B1 (xx)
JP (3) JP2010502652A (xx)
KR (1) KR101501660B1 (xx)
CN (2) CN103044550A (xx)
AU (1) AU2007290145B2 (xx)
BR (1) BRPI0715660B8 (xx)
CA (1) CA2660175C (xx)
CY (1) CY1115939T1 (xx)
DK (1) DK2594586T3 (xx)
ES (2) ES2548714T3 (xx)
HK (1) HK1199047A1 (xx)
IL (1) IL196914A (xx)
MX (1) MX2009002242A (xx)
PL (1) PL2594586T3 (xx)
PT (1) PT2594586E (xx)
RU (1) RU2009111884A (xx)
SI (1) SI2594586T1 (xx)
WO (1) WO2008028192A2 (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060090A2 (en) 2002-01-18 2003-07-24 Zymogenetics, Inc. Novel cytokine zcytor17 ligand
MX2007009718A (es) 2005-02-14 2007-09-26 Zymogenetics Inc Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra.
AU2006214326B2 (en) * 2005-02-14 2011-09-29 National Jewish Medical And Research Center Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
EP2594585A1 (en) 2006-01-10 2013-05-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
ES2548714T3 (es) * 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
EP2061496A2 (en) 2007-01-10 2009-05-27 Zymogenetics, Inc. Methods of using il-31 to treat airway hyper-responsiveness and asthma
PT2796466T (pt) * 2007-12-07 2018-02-23 Zymogenetics Inc Moléculas de anticorpo humanizado específicas para il-31
CA2726512A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103965363B (zh) * 2013-02-06 2021-01-15 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
NZ713636A (en) 2013-05-30 2022-07-01 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
JP6085746B2 (ja) * 2014-08-11 2017-03-01 学校法人北里研究所 抗トロンボポエチン抗体の検出における検出感度の向上方法、免疫性血小板減少症の検出方法及びキット
JP6302813B2 (ja) * 2014-09-30 2018-03-28 日立ジョンソンコントロールズ空調株式会社 スクロール圧縮機及びこれを用いた冷凍サイクル装置
WO2016167263A1 (ja) * 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
AU2016248786B2 (en) 2015-04-14 2022-01-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient
US11073670B2 (en) 2016-08-12 2021-07-27 Corning Optical Communications LLC Device and method for sealing multiport splitters
EP3554515A4 (en) * 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US10359577B2 (en) 2017-06-28 2019-07-23 Corning Research & Development Corporation Multiports and optical connectors with rotationally discrete locking and keying features
US11668890B2 (en) 2017-06-28 2023-06-06 Corning Research & Development Corporation Multiports and other devices having optical connection ports with securing features and methods of making the same
AU2017421285B2 (en) 2017-06-28 2024-03-28 Corning Research & Development Corporation Compact fiber optic connectors, cable assemblies and methods of making the same
US11300746B2 (en) 2017-06-28 2022-04-12 Corning Research & Development Corporation Fiber optic port module inserts, assemblies and methods of making the same
US11187859B2 (en) 2017-06-28 2021-11-30 Corning Research & Development Corporation Fiber optic connectors and methods of making the same
WO2019086694A1 (en) * 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
CN112020511A (zh) 2018-03-16 2020-12-01 硕腾服务有限责任公司 用于兽医用途的白介素-31单克隆抗体
US10641967B1 (en) 2018-11-16 2020-05-05 Corning Research & Development Corporation Multiport assemblies including a modular adapter support array
US10768382B2 (en) 2018-11-29 2020-09-08 Corning Research & Development Corporation Multiport assemblies including access apertures and a release tool
CN109528663A (zh) * 2018-12-20 2019-03-29 江西润泽药业有限公司 以ngr(no2)为靶向载体的抗癌药物冻干粉剂及其制备方法和应用
EP3958903A4 (en) * 2019-04-24 2023-08-02 Janssen Biotech, Inc. ANTIBODY FORMULATION
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
US11294133B2 (en) 2019-07-31 2022-04-05 Corning Research & Development Corporation Fiber optic networks using multiports and cable assemblies with cable-to-connector orientation
AU2020336210A1 (en) * 2019-08-29 2022-03-03 Elanco Us Inc. Anti-IL31 antibodies for veterinary use
US11487073B2 (en) 2019-09-30 2022-11-01 Corning Research & Development Corporation Cable input devices having an integrated locking feature and assemblies using the cable input devices
EP3805827A1 (en) 2019-10-07 2021-04-14 Corning Research & Development Corporation Fiber optic terminals and fiber optic networks having variable ratio couplers
US11650388B2 (en) 2019-11-14 2023-05-16 Corning Research & Development Corporation Fiber optic networks having a self-supporting optical terminal and methods of installing the optical terminal
KR102416078B1 (ko) 2019-11-20 2022-07-01 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
US11536921B2 (en) 2020-02-11 2022-12-27 Corning Research & Development Corporation Fiber optic terminals having one or more loopback assemblies
EP4209227A4 (en) 2020-09-01 2024-05-29 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF PRURITUS IN DIALYSIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE INGREDIENT
US11604320B2 (en) 2020-09-30 2023-03-14 Corning Research & Development Corporation Connector assemblies for telecommunication enclosures
US11686913B2 (en) 2020-11-30 2023-06-27 Corning Research & Development Corporation Fiber optic cable assemblies and connector assemblies having a crimp ring and crimp body and methods of fabricating the same
US11880076B2 (en) 2020-11-30 2024-01-23 Corning Research & Development Corporation Fiber optic adapter assemblies including a conversion housing and a release housing
US11927810B2 (en) 2020-11-30 2024-03-12 Corning Research & Development Corporation Fiber optic adapter assemblies including a conversion housing and a release member
EP4019547A1 (en) * 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
WO2022136675A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains that bind il-4r
EP4019546A1 (en) * 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-31
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
US11947167B2 (en) 2021-05-26 2024-04-02 Corning Research & Development Corporation Fiber optic terminals and tools and methods for adjusting a split ratio of a fiber optic terminal
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用
CN117589031B (zh) * 2024-01-19 2024-03-19 四川铁道职业学院 一种受电弓碳滑板磨损检测工具及其检测方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co MICROORGANISM PRODUCING TRYPTOPHANE.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ZA894792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
NZ229700A (en) 1988-06-24 1993-01-27 Dow Chemical Co Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69130709T3 (de) 1990-10-05 2005-12-22 Celldex Therapeutics, Inc. Gezielte immunostimulierung mit bispezifischen stoffen
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
JPH0578243A (ja) * 1990-12-11 1993-03-30 Shiseido Co Ltd 鎮痒剤及び鎮痒組成物
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0511011B1 (en) 1991-04-26 1996-10-23 Surface Active Limited Novel antibodies and methods for their use
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
WO1994004670A1 (en) 1992-08-26 1994-03-03 President And Fellows Of Harvard College Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
ATE331438T1 (de) 1995-01-17 2006-07-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelealer transport von immunogenen
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
PT1325115T (pt) 2000-06-26 2016-09-28 Zymogenetics Inc Recetor de citocina zcytor17
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2003060090A2 (en) 2002-01-18 2003-07-24 Zymogenetics, Inc. Novel cytokine zcytor17 ligand
SI1576112T1 (sl) 2002-01-18 2012-10-30 Zymogenetics Inc Multimerni citokinski receptor zcitor17
US20050097625A1 (en) * 2002-11-27 2005-05-05 Meade Harry M. Modified antibodies stably produced in milk and methods of producing same
CA2580981C (en) * 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20060228329A1 (en) 2005-01-28 2006-10-12 Brady Lowell J Homogeneous preparations of IL-31
AU2006214326B2 (en) 2005-02-14 2011-09-29 National Jewish Medical And Research Center Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
MX2007009718A (es) 2005-02-14 2007-09-26 Zymogenetics Inc Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra.
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20130216542A1 (en) * 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2594585A1 (en) 2006-01-10 2013-05-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
ES2548714T3 (es) * 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
PT2796466T (pt) 2007-12-07 2018-02-23 Zymogenetics Inc Moléculas de anticorpo humanizado específicas para il-31

Also Published As

Publication number Publication date
EP2594586B1 (en) 2014-08-27
AU2007290145A1 (en) 2008-03-06
JP6174481B2 (ja) 2017-08-02
EP2594586A1 (en) 2013-05-22
CN101522713A (zh) 2009-09-02
CY1115939T1 (el) 2017-01-25
US9011858B2 (en) 2015-04-21
US9878038B2 (en) 2018-01-30
EP2759549B1 (en) 2015-08-19
US20130266562A1 (en) 2013-10-10
WO2008028192A2 (en) 2008-03-06
US9624296B2 (en) 2017-04-18
EP2759549A2 (en) 2014-07-30
IL196914A (en) 2014-12-31
US20100008909A1 (en) 2010-01-14
US20170182160A1 (en) 2017-06-29
PT2594586E (pt) 2014-11-26
ES2519375T3 (es) 2014-11-06
KR101501660B1 (ko) 2015-03-11
PL2594586T3 (pl) 2015-02-27
US20150183869A1 (en) 2015-07-02
US10434173B2 (en) 2019-10-08
US20190374637A1 (en) 2019-12-12
BRPI0715660A2 (pt) 2013-07-02
CN103044550A (zh) 2013-04-17
ES2548714T3 (es) 2015-10-20
WO2008028192A3 (en) 2008-05-15
CA2660175C (en) 2015-05-12
JP2010502652A (ja) 2010-01-28
MX2009002242A (es) 2009-03-13
JP2016106105A (ja) 2016-06-16
CA2660175A1 (en) 2008-03-06
EP2061811A2 (en) 2009-05-27
BRPI0715660B8 (pt) 2021-05-25
SI2594586T1 (sl) 2014-11-28
KR20090113818A (ko) 2009-11-02
EP2759549A3 (en) 2014-08-27
US20190038743A1 (en) 2019-02-07
DK2594586T3 (en) 2014-11-17
US8466262B2 (en) 2013-06-18
IL196914A0 (en) 2011-08-01
JP2014122220A (ja) 2014-07-03
AU2007290145B2 (en) 2012-11-01
BRPI0715660B1 (pt) 2018-06-19
RU2009111884A (ru) 2010-10-10

Similar Documents

Publication Publication Date Title
HK1199047A1 (en) Il-31 monoclonal antibodies and methods of use il-31
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
HUS2000026I1 (hu) Anti-CD79b antitestek és immunkonjugátumok és alkalmazási eljárások
HK1223114A1 (zh) 抗因子 單克隆抗體及其使用方法
EP2021029A4 (en) HUMANIZED FC RIB SPECIFIC ANTIBODIES AND METHOD FOR THEIR USE
IL195573A0 (en) Fc??RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL196550A0 (en) Anti-il-6 monoclonal antibodies and uses thereof
EP2086583A4 (en) FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE
ZA200903775B (en) Human monoclonal antibodies to BTLA and methods of use
HK1099935A1 (en) Anti-cd3 antibodies and methods of use thereof -cd3
IL198020A0 (en) Anti-cd20 antibodies and methods of use
ZA200805741B (en) Anti-MN antibodies and methods of using same
EP2185719A4 (en) RANTES ANTIBODIES AND METHOD FOR THEIR USE
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE
EP2048162A4 (en) NEW MONOCLONAL ANTIBODY AND ITS USE
SI1919951T1 (sl) Anti-tnf-alfa protitelesa in postopki za uporabo
AU2013257515A1 (en) Humanized anti-CD79b antibodies and immunoconjugates and methods of use